Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 20:21 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Study to Assess the Efficacy and Safety of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP)
NCT04274452 · argenx · PHASE3 · withdrawn · last registry update 2020-09-14 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “The ARGX-113-1908 study will be replaced by a similar design with a subcutaneous formulation (ARGX-113-2004)” | – | Registry record, argenx |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against FCGRT within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2021-08-03Results posted on the registry: UCB Biopharma S.P.R.L., UCB7665 (NCT03052751)
- 2021-07-07Phase 3 first posted: Janssen Research & Development, LLC, Nipocalimab + Placebo (NCT04951622)
- 2021-01-08Results posted on the registry: argenx, ARGX-113 + Placebo (NCT02965573)
- 2020-12-03Phase 3 first posted: UCB Biopharma SRL, Rozanolixizumab (NCT04650854)
- 2020-10-22Phase 3 first posted: UCB Biopharma SRL, Rozanolixizumab (NCT04596995)
- 2020-07-13Also stopped (withdrawn): Alexion Pharmaceuticals, Inc., ALXN1830 (NCT04256148)
- 2020-05-13Results posted on the registry: Alexion Pharmaceuticals, Inc., ALXN1830 (NCT03075878)
- 2020-05-13Also stopped (terminated): Alexion Pharmaceuticals, Inc., ALXN1830 (NCT03075878)
- 2020-02-05Results posted on the registry: Alexion Pharmaceuticals, Inc., ALXN1830 (NCT03075904)
- 2020-02-05Also stopped (terminated): Alexion Pharmaceuticals, Inc., ALXN1830 (NCT03075904)
- 2020-01-13Phase 3 first posted: argenx, efgartigimod (NCT04225156)
- 2020-01-13Phase 3 first posted: UCB Biopharma SRL, Rozanolixizumab (NCT04224688)
- 2019-12-16Phase 3 first posted: UCB Biopharma SRL, Rozanolixizumab (NCT04200456)
- 2019-12-05Phase 3 first posted: argenx, efgartigimod (NCT04188379)
- 2019-10-14Phase 3 first posted: UCB Biopharma SRL, Rozanolixizumab (NCT04124965)
- 2019-10-08Phase 3 first posted: Janssen Research & Development, LLC, M281 + Placebo (NCT04119050)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision